{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ellipticines : Questions médicales les plus fréquentes",
"headline": "Ellipticines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ellipticines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ellipticines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carbazoles",
"url": "https://questionsmedicales.fr/mesh/D002227",
"about": {
"@type": "MedicalCondition",
"name": "Carbazoles",
"code": {
"@type": "MedicalCode",
"code": "D002227",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.300.148"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ellipticines",
"alternateName": "Ellipticines",
"code": {
"@type": "MedicalCode",
"code": "D004611",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elaine C O'Sullivan",
"url": "https://questionsmedicales.fr/author/Elaine%20C%20O%27Sullivan",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Florence O McCarthy",
"url": "https://questionsmedicales.fr/author/Florence%20O%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Hao Lu",
"url": "https://questionsmedicales.fr/author/Hao%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Manli Liu",
"url": "https://questionsmedicales.fr/author/Manli%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Hubei Biopesticide Engineering Research Centre, Hubei Academy of Agricultural Sciences, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Wenjia Lu",
"url": "https://questionsmedicales.fr/author/Wenjia%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Penalized maximum likelihood inference under the mixture cure model in sparse data.",
"datePublished": "2023-03-25",
"url": "https://questionsmedicales.fr/article/36964996",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/sim.9715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A progressive three-state model to estimate time to cancer: a likelihood-based approach.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35761181",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12874-022-01645-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neural networks underlying visual illusions: An activation likelihood estimation meta-analysis.",
"datePublished": "2023-08-15",
"url": "https://questionsmedicales.fr/article/37591478",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neuroimage.2023.120335"
}
},
{
"@type": "ScholarlyArticle",
"name": "Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37248751",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/sim.9807"
}
},
{
"@type": "ScholarlyArticle",
"name": "Likelihood-based signal and noise analysis for docking of models into cryo-EM maps.",
"datePublished": "2023-03-15",
"url": "https://questionsmedicales.fr/article/36920335",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1107/S2059798323001596"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérocycliques 3 noyaux",
"item": "https://questionsmedicales.fr/mesh/D006575"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carbazoles",
"item": "https://questionsmedicales.fr/mesh/D002227"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ellipticines",
"item": "https://questionsmedicales.fr/mesh/D004611"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ellipticines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ellipticines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ellipticines",
"description": "Comment diagnostiquer une tumeur sensible aux ellipticines ?\nQuels tests sont utilisés pour évaluer l'efficacité des ellipticines ?\nLes ellipticines sont-elles utilisées pour tous les types de cancer ?\nQuels signes cliniques indiquent un traitement par ellipticines ?\nComment évaluer les effets secondaires des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ellipticines",
"description": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?\nLes ellipticines provoquent-elles des effets secondaires ?\nComment reconnaître une réaction allergique aux ellipticines ?\nLes ellipticines affectent-elles le système immunitaire ?\nQuels signes indiquent une toxicité des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ellipticines",
"description": "Peut-on prévenir les cancers traités par ellipticines ?\nQuels facteurs de risque sont associés aux cancers traités par ellipticines ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?\nComment un mode de vie sain influence-t-il le risque de cancer ?\nLes examens de santé réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ellipticines",
"description": "Comment les ellipticines sont-elles administrées ?\nLes ellipticines sont-elles utilisées en monothérapie ?\nQuel est le mécanisme d'action des ellipticines ?\nQuelles sont les alternatives aux ellipticines ?\nComment surveiller l'efficacité du traitement par ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ellipticines",
"description": "Quelles complications peuvent survenir avec les ellipticines ?\nLes ellipticines peuvent-elles causer des dommages aux organes ?\nComment gérer les effets secondaires graves des ellipticines ?\nLes ellipticines augmentent-elles le risque de récidive du cancer ?\nQuels sont les risques de surdosage d'ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ellipticines",
"description": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?\nL'hérédité joue-t-elle un rôle dans le risque de cancer ?\nL'alimentation influence-t-elle le risque de cancer ?\nLe stress est-il un facteur de risque pour le cancer ?\nLes infections virales augmentent-elles le risque de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Likelihood+Functions&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur sensible aux ellipticines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par biopsie et analyses histopathologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des ellipticines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM et des marqueurs tumoraux sont utilisés."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont principalement efficaces contre certains cancers comme le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un traitement par ellipticines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de progression tumorale ou de résistance aux autres traitements peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des ellipticines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des examens cliniques et des questionnaires de qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, fatigue, perte de poids et changements d'appétit."
}
},
{
"@type": "Question",
"name": "Les ellipticines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent causer nausées, vomissements, et troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux ellipticines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Les ellipticines affectent-elles le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une toxicité des ellipticines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de toxicité incluent fatigue extrême, saignements inhabituels et jaunisse."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les cancers traités par ellipticines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives incluent un mode de vie sain et des dépistages réguliers."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux cancers traités par ellipticines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition à des agents carcinogènes et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il le risque de cancer ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant alimentation équilibrée et exercice, peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les examens de santé réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement des anomalies et d'initier un traitement rapide."
}
},
{
"@type": "Question",
"name": "Comment les ellipticines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse ou orale."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées en monothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées seules ou en association avec d'autres traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des ellipticines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles agissent en interférant avec l'ADN des cellules cancéreuses, inhibant leur prolifération."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives aux ellipticines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les alternatives incluent d'autres chimiothérapies, thérapies ciblées et immunothérapies."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement par ellipticines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par des examens d'imagerie et des bilans sanguins réguliers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les ellipticines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des saignements et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les ellipticines peuvent-elles causer des dommages aux organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des toxicités hépatiques et rénales, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires graves des ellipticines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'ajustement de la dose, l'utilisation de médicaments symptomatiques et le suivi."
}
},
{
"@type": "Question",
"name": "Les ellipticines augmentent-elles le risque de récidive du cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire le risque de récidive, mais un suivi régulier est essentiel."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de surdosage d'ellipticines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le surdosage peut entraîner des effets toxiques graves, nécessitant une intervention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent le tabagisme, l'exposition à des produits chimiques et l'âge."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le risque de cancer ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer certaines tumeurs."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de cancer ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en fruits et légumes peut réduire le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour le cancer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que le stress ne soit pas un facteur direct, il peut affecter le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections virales augmentent-elles le risque de cancer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales, comme le HPV, sont liées à un risque accru de cancer."
}
}
]
}
]
}
When a study sample includes a large proportion of long-term survivors, mixture cure (MC) models that separately assess biomarker associations with long-term recurrence-free survival and time to disea...
We extend Firth-type penalized likelihood (FT-PL) developed for bias reduction in the exponential family to the Weibull-logistic MC, using the Jeffreys invariant prior. Via simulation studies based on...
In samples with relatively few events, the Firth-type penalized likelihood estimates (FT-PLEs) have mean bias closer to zero and smaller mean squared error than maximum likelihood estimates (MLEs), an...
Consistent with findings for logistic and Cox regressions, FT-PL under MC regression yields finite estimates under stringent conditions, and better bias-and-variance balance than the other two penaliz...
To optimize colorectal cancer (CRC) screening and surveillance, information regarding the time-dependent risk of advanced adenomas (AA) to develop into CRC is crucial. However, since AA are removed af...
Sixteen models were specified, with and without covariates. Parameters of the parametric time-to-event distributions from the adenoma-free state (AF) to AA and from AA to CRC were estimated simultaneo...
Estimates of the parameters of the time distributions are consistent and the 95% confidence intervals (CIs) have good coverage. For the Norwegian sample (AF: 78%, AA: 20%, CRC: 2%), a Weibull model fo...
The time-dependent risk from AA to CRC is crucial to explain differences in the outcomes of microsimulation models used for the optimization of CRC prevention. Our method allows for improving models b...
Visual illusions have long been used to study visual perception and contextual integration. Neuroimaging studies employ illusions to identify the brain regions involved in visual perception and how th...
In vaccine clinical trials, vaccine efficacy endpoint analysis is usually associated with in high cost or extended study duration, due to the generally low infection rate. Correlate of protection (CoP...
Fast, reliable docking of models into cryo-EM maps requires understanding of the errors in the maps and the models. Likelihood-based approaches to errors have proven to be powerful and adaptable in ex...
The diagnostic accuracy of multiple biomarkers in medical research is crucial for detecting diseases and predicting patient outcomes. An optimal method for combining these biomarkers is essential to m...
Pairwise maximum likelihood (PML) estimation is a promising method for multilevel models with discrete responses. Multilevel models take into account that units within a cluster tend to be more alike ...
COVID-19 country spikes have been reported at varying temporal scales as a result of differences in the disease-driving factors. Factors affecting case load and mortality rates have varied between cou...
Nonparametric maximum likelihood estimation encompasses a group of classic methods to estimate distribution-associated functions from potentially censored and truncated data, with extensive applicatio...
Maximum likelihood estimation is among the most widely-used methods for inferring phylogenetic trees from sequence data. This paper solves the problem of computing solutions to the maximum likelihood ...